Risk factors and incidence of thrombosis in a Brazilian cohort of patients with Philadelphia-negative myeloproliferative neoplasms
- 2 January 2020
- journal article
- research article
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 49 (4) , 667-672
Abstract
Few data are available regarding epidemiology and outcomes of Philadelphia-negative chronic myeloproliferative neoplasms (MPN) in Latin America. Therefore, current models for MPN treatment are based in large cohorts of patients from Europe and North America. In this paper, we conducted a retrospective study to evaluate thrombotic and bleeding events in a cohort of patients with MPN from a reference center in Brazil. A total of 334 patients were included, being essential thrombocythemia the most common diagnosis. Here, we found that 41% of the MPN patients had a thrombotic event prior to the diagnosis. Thrombosis was more frequent in patients under 60 years-old. In a multivariable model, only JAK2 V617F mutation (OR 2.57 95% CI 1.58–4.18, p < 0.001) and presence of two cardiovascular risk factors (OR 1.90 95% CI 1.21–2.98, p < 0.005) were significant for thrombosis. The risk of thrombosis was similar among all subtypes of MPN. Cumulative incidence of thromboembolic event at 5 years from diagnosis was 5.8% (95% CI 3.5–8.9), which is similar to previous studies. The high incidence of thromboembolic events in younger patients suggests that socioeconomic disparities might have a role in the outcomes of MPNKeywords
This publication has 28 references indexed in Scilit:
- 3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease SubgroupsMayo Clinic Proceedings, 2019
- Polycythemia vera treatment algorithm 2018Blood Cancer Journal, 2018
- Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registryJournal of Hematology & Oncology, 2016
- Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemiaBlood Cancer Journal, 2015
- JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomesBlood, 2014
- Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisalLeukemia, 2008
- Leukocytosis as a major thrombotic risk factor in patients with polycythemia veraBlood, 2006
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005
- Efficacy and Safety of Low-Dose Aspirin in Polycythemia VeraNew England Journal of Medicine, 2004
- The myeloproliferative disordersDisease-a-Month, 1970